Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Clinical trial NCT05845671 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05845671
Sponsor: University of Colorado, Denver
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lung Cancer Non Small Cell Lung Cancer

Start date: 2023-07-17
Primary completion: 2027-01-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.